Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux
NCT: NCT06678997 · COMPLETED
Brief Summary
The goal of this clinical trial is to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants with GER. Researchers will compare Zinc-L carnosine/Polaprezinc to a placebo (a look-alike substance that contains no drug) to see if Zinc-L carnosine/Polaprezinc works to treat infants with GER. Participants will: Take drug Zinc-L carnosine/Polaprezinc or a thickened formula every day for 8 weeks Visit the clinic once every 4 weeks for checkups and questionnaires
Frequently Asked Questions
What is Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux?
Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux is a clinical trial registered under NCT06678997. Current status: COMPLETED.
What is the status of NCT06678997?
The current status of NCT06678997 (Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux) is: COMPLETED.
When did Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux start?
Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux started on 2024-12-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.